First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol, Guido Kroemer, Lorenzo Galluzzi

    Research output: Contribution to journalEditorial

    254 Citations (Scopus)

    Abstract

    On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

    Original languageEnglish
    Article numbere1115641
    JournalOncoImmunology
    Volume5
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 2016

    Keywords

    • Granulocyte macrophage colony-stimulating factor
    • Imlygic®
    • OPTiM
    • OncoVEX
    • T-vec
    • talimogene laherparepvec

    Cite this